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The new Medicare Drug Benefit: Much ado About Little?
Abstract
After many years of debate, Congress recently approved a new, voluntary “Medicare Part D” benefit that
provides some coverage for prescription drugs. The goal of this coverage is to reduce financial barriers
that might prevent beneficiaries from obtaining needed drugs. The degree to which this goal is achieved
depends on how well the benefit reaches seniors with previously unmet needs; conversely, it may do little
to improve seniors’ health if it replaces existing sources of coverage, or encourages overuse of drugs.
This Issue Brief reviews data on current patterns of drug spending among Medicare beneficiaries and
summarizes aspects of the new benefit. It explores the likely effect of the coverage on overall use of and
spending for prescription drugs and considers whether any additional use is likely to represent needed
care that had been forgone because of a cost barrier.
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The New Medicare Drug Benefit:
Much Ado About Little?

Some Medicare
beneficiaries have high
drug spending, but most
of them are not poor

In 2000, Medicare beneficiaries spent an average of $1500 per person on
prescription drugs, about $550 of which they paid out-of-pocket. However,
the majority of drug spending is concentrated among a small group. About
26% of enrollees spent $2000 or more and accounted for 65% of total drug
spending in the Medicare population. Anecdotes about seniors going without
needed drugs because of cost provided the impetus for adding coverage for
prescription drugs to Medicare.

Editor’s Note: After many years of debate, Congress recently approved a new,
voluntary “Medicare Part D” benefit that provides some coverage for
prescription drugs. The goal of this coverage is to reduce financial barriers
that might prevent beneficiaries from obtaining needed drugs. The degree to
which this goal is achieved depends on how well the benefit reaches seniors
with previously unmet needs; conversely, it may do little to improve seniors’
health if it replaces existing sources of coverage, or encourages overuse of
drugs. This Issue Brief reviews data on current patterns of drug spending
among Medicare beneficiaries and summarizes aspects of the new benefit.
It explores the likely effect of the coverage on overall use of and spending for
prescription drugs and considers whether any additional use is likely to
represent needed care that had been forgone because of a cost barrier.

• Prior to the new benefit, about 75% of Medicare beneficiaries had some
drug coverage. In 2000, 30% had drug coverage through employer- or
union-sponsored retiree benefits, 16% through Medicaid, 12% through
individually-purchased Medigap policies, and 17% through a Medicare
managed care plan, or other state or federal program. The extent of this
coverage varies, with retiree plans offering more extensive benefits, and
Medigap policies providing more limited coverage.
• Compared with those lacking drug coverage, those with coverage fill about
28% more prescriptions per year (32 versus 35) and in 2003 will spend
about twice as much on drugs ($2700 versus $1400).
Continued on next page.

• Not all those lacking drug coverage are poor. About 31% of beneficiaries
are poor or near poor [100%-150% of federal poverty level (FPL)], 33%
are “tweeners” (between 151% and 300% of FPL), and 35% are not poor
(more than 300% of FPL). The proportion without drug coverage is about
even across income categories, as Medicaid coverage for the poor group
offsets the choice of private drug coverage among the non-poor. About
10% of the Medicare population is both poor and lacking in drug
coverage.
• The poor account for the highest proportion of total drug spending
(35%), but because of generous Medicaid coverage, the average percentage
paid out of pocket is actually lowest for them (33%, vs. 45% for the
“tweeners” and 40% for the non-poor). However, the subset of the poor
not covered by Medicaid pay the highest percentage of their drug costs
out-of-pocket.

New Medicare prescription
drug benefit leaves
“doughnut hole” in
coverage

After an interim period where beneficiaries can buy a discount prescription
drug card, the new Medicare Part D provides subsidized drug insurance
beginning in 2006. All beneficiaries will have access to coverage through
private prescription drug plans that contract with Medicare or through
private health plans that offer drug coverage along with other health care
services. Enrollment is voluntary.
• In 2006, beneficiaries choosing the new benefit will pay a premium of
about $420 per year ($35 per month), with an annual deductible of $250.
The amounts of premiums, deductibles and copayments are all tied to
yearly increases in total drug spending; thus, if total drug spending
increases beyond inflation, these out-of-pocket payments will rise as well.
• The standard package provides 75% coverage for the first $2000 of drug
spending beyond the deductible. At that point, coverage stops for the next
$2850 of expenses. After expenses of $5100 ($3600 in out-of-pocket
costs), nearly complete coverage kicks in, with 95% coverage of additional
expenses and minimal per-prescription copayments. This unusual gap in
coverage, (often called the “doughnut hole”) was included to limit the
federal cost of the new benefit. The graph on page 3 illustrates the
benefits provided at different levels of drug spending.
• The benefit provides significant additional assistance for low-income
beneficiaries, including those eligible for Medicaid. Beneficiaries with
incomes less than 150% of the federal poverty level will pay little or no
premiums or deductibles, and will not have the “doughnut hole” in
coverage.
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Medicare Part D coverage,
for seniors with incomes
greater than 150% of
Federal Poverty Level

Who benefits from the new
benefit?

The net benefits of Medicare Part D will be different for different types of
beneficiaries. Poor or near-poor beneficiaries without previous drug coverage
(10% of all beneficiaries) will reap the most benefits because they will not
face high premiums, copayments, or gaps in coverage.
• The new coverage will not help the great bulk of beneficiaries with
employer- or union-based coverage, most of whom have better benefits and
lower premiums. To discourage employers from dropping or limiting drug
coverage for retirees, the new law provides a 28% subsidy to employers
offering equivalent coverage to Medicare Part D for drug costs between
$250 and $5000.
• Beneficiaries with existing Medicaid drug coverage will be enrolled in the
new Medicare benefit, with minimal per-prescription copayments.
However, because of the generosity of most state Medicaid plans, these
“dual eligibles” are likely to gain little from having their drug expenses
covered under Medicare.
• Those with privately-purchased Medigap policies will likely benefit,
because of the high premiums and coverage limitations of most Medigap
policies. The new law bans Medigap drug coverage for Medicare Part D
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enrollees, but permits them to enroll in drug plans with more generous
coverage than the minimum at higher premiums.
• For “tweeners” and non-poor beneficiaries who previously had no drug
coverage, the new Medicare benefit may or may not be helpful. The
“magic number” is $810 in drug expenses per year, the point at which the
Medicare benefit received begins to exceed the $420 premium.

Medicare Part D coverage
will likely have a very
small impact on overall
drug spending

Pauly analyzed the likely impact of the Medicare benefit on drug spending,
given existing evidence that people generally use more, and more costly,
health services when insurance covers all or part of the cost. Economists call
this aspect of insurance the theory of “moral hazard.” Not all moral hazard is
undesirable or avoidable, but at least some of it can lead to overuse of drugs
of little health benefit.
• Existing research in the non-elderly suggests that individual demand for
drugs depends strongly on the out-of-pocket price. Estimates indicate that
a 10% drop in the average cost of drugs to consumers can lead to a 3%-4%
increase in the quantity of drugs purchased. The Congressional Budget
Office estimates that Medicare coverage will have little or no effect on drug
prices, as more aggressive bargaining by private drug plans reduces the
higher prices typically charged to the uninsured.
• To estimate the likely “moral hazard” effect of Medicare Part D, Pauly
assumed no change in coverage (and drug spending) for those with existing
Medicaid or employment-based coverage, or for those with managed care
plans. He assumed that people without coverage and those with Medigap
would enroll in the new program.
• Congress estimated that about 47% of total drug spending by Medicare
beneficiaries would be covered by the new Medicare benefit. Pauly
assumed that, in the aggregate, the benefit reduces the user (out-of-pocket)
price of any drug by 47% for beneficiaries without current drug coverage,
and by about 14% on average for beneficiaries with more limited Medigap
coverage.
• Using these figures, Pauly estimated that total drug spending for Medicare
beneficiaries (if prices were unchanged) would rise by just 5.64%. Use
would expand by 20% for those who formerly had no coverage and by 6%
for those formerly having Medigap coverage. If the new coverage displaced
more generous employer-provided or health plan coverage, the increase in
spending would be even smaller.

Continued on page 5.
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New benefit not likely to
have much impact on
average health

Pauly considered how much of this increase in drug spending might be
desirable and appropriate, and how much might be “wasted” in terms of
overuse of drugs among seniors not facing financial barriers. How would the
increase in spending be distributed among the three income categories?
• Pauly estimated that the increase in drug spending would be distributed
virtually equally among the three income groups, since the slightly higher
percentage uninsured for drugs among the poor is offset by a higher
percentage with less generous Medigap coverage among the other two
groups.
• The calculations assume that the non-poor (with incomes of more than
300% of FPL) face no financial barriers to needed drugs, and so their 33%
of the increase in spending is “wasted.” They also assume that that the
“tweeners” could afford up to the 25% of spending below $2000 per year,
and so 8% of their spending increase (33% x 25%) is wasted.
• Thus, Pauly concludes that 41% of the small increase in overall Medicare
drug spending would be wasted, in terms of increasing use among
beneficiaries not facing financial barriers. The remaining 3.3% increase in
use and spending would be regarded by this criterion as socially desirable.
• Although the estimates are approximations, the message is one of how
small an impact, for good or ill, the prescription benefit program is likely
to have. The modest effect on total use means that even under the most
optimistic circumstances, the Medicare drug coverage benefit will not, in
the aggregate, do much to increase access, improve efficiency in the use of
medical care, improve health outcomes, or increase drug company profits.
For the small part of the population whose use is affected, there may be
modest improvements in health care and health (but probably not as large
as if the benefit program were more targeted).

POLICY IMPLICATIONS

Reasonable estimates of the effect of the Medicare drug benefit on drug
spending strongly suggest that the spending increase will be small and that
some of it will go to beneficiaries who do not face high financial barriers at
present. Thus, from the viewpoint of improvements in health or national
spending on drugs, effects are minimal. The effects on Medicare’s fiscal future
are much more important.
• A sizable portion of the new coverage does not provide protection against
catastrophic drug costs, but instead provides “coverage” of much lower
value for relatively small and certain drug expenses. Most of the benefit
will go to pay for drug expenses that people are already making–but it
shifts those expenses from out of the beneficiary’s pocket at the point of use
to taxpayers’ pockets. In other words, the main effect of the new benefit
will be one of transfers of money, not changes in medical care or health.
Continued on back.
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POLICY IMPLICATIONS
Continued

• The new benefit represents a political compromise, in that legislators did
not want to offer only catastrophic coverage that they felt would be
attractive only to the minority of seniors with very high drug expenses.
The current design allows more people to “make money” from insurance
even as it imposes higher out-of-pocket costs on some seniors with
catastrophic expenses.
• Recent estimates of the 10-year cost of the benefit have risen from $400
billion to $536 billion, based largely on higher estimates of the number of
beneficiaries who would take the subsidized coverage. It is reasonable to
question whether the current benefit, as designed, is the best (or even a
good) way to add drug coverage to Medicare.
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